- Home
- / Whitepapers
- / Blood-Based Biomarker Solutions for Cancer Therapy Associated Neurotoxicities
Blood-Based Biomarker Solutions for Cancer Therapy Associated Neurotoxicities
Posted on
Download nowPublication Brief
Cancer therapy-associated neurotoxicities can exert debilitating effects on patients and negatively impact the course of cancer treatment. There is a critical need for accurate biomarker tests that could predict the onset as well as assess the severity of neurotoxicities. In addition, such tests could potentially provide realtime feedback to clinicians during treatment to proactively adjust or fine-tune cancer therapy regimen and for supportive care for patients who experience acute or long-term toxicities. Recent data from a number of clinical studies have shown that blood-based Simoa® biomarker assays (NfL, etc.) are promising as predictive and quantitative biomarkers for cancer therapy associated neurotoxicities. Download our publication brief to learn more.
Share This Post
Related Posts
Mapping the Tau Cascade: New Insights from p-Tau 205 and p-Tau 212 for Disease Staging and Monitoring
NPTX2: A Synaptic Biomarker of Circuit Integrity, Cognitive Resilience, and Neurodegeneration
Advancing Translational Neuroscience with the Simoa Mammalian GFAP Assay
Publication Brief Understanding astrocyte biology is essential for advancing translational neuroscience. GFAP has emerged as a leading biomarker of CNS injury, and Simoa® technology now enables its ultra-sensitive detection directly…
Proteomics in Transition: From Discovery to Diagnostic Relevance
Proteomics is moving beyond broad discovery to deliver real-time, clinically meaningful insights. At the forefront is Quanterix’s Simoa® digital immunoassay technology, enabling ultra-sensitive, reproducible detection of low-abundance biomarkers in areas…
Beyond Blood: Expanding Simoa Applications in Urine, Saliva, Sweat, and Tears
Publication Brief The Quanterix Simoa® platform, known for ultrasensitive detection in plasma, serum, and CSF, now delivers the same performance in alternative matrices—urine, saliva, sweat, and tears. This publication brief…
Simoa® IL-17A Advantage PLUS: Potential Biomarker Applications in Health and Disease
App Note IL-17A is a potent pro-inflammatory cytokine that plays critical roles in inflammatory responses, host defense against infections, and tissue regeneration. This application note delves into the physiological and…
Beyond Blood: Tear Fluid as a Window into Biomarker Discovery
While blood and CSF have long dominated biomarker research, tear fluid is emerging as a scientifically relevant, non-invasive matrix for detecting systemic and neurological biomarkers. Produced by lacrimal glands and…
Sweat As A Non-Invasive Matrix for Cytokine Detection Using Simoa®
Inflammatory cytokines like IL-6, IL-10, and TNF-α are central to understanding aging, immune dysregulation, and chronic disease. With eccrine glands distributed across the body, sweat offers a non-invasive, physiologically relevant…